Skip to main content
PMC home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1986 Apr 19;292(6527):1037–1039. doi: 10.1136/bmj.292.6527.1037

Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon.

I A Reilly, L Roy, G A Fitzgerald
PMCID: PMC1340106  PMID: 3083991

Abstract

Thromboxane A2, the predominant cyclo-oxygenase product of arachidonic acid in platelets, is a potent vasoconstrictor and platelet agonist. Analysis of urinary metabolites by gas chromatography and mass spectrometry is a specific non-invasive method of measuring the biosynthesis of thromboxane that avoids the problem of platelet activation ex vivo. Excretion of the major urinary thromboxane metabolite, 2,3-dinor-thromboxane B2, was significantly increased (p less than 0.001) in 10 patients (nine women) with systemic sclerosis complicated by Raynaud's phenomenon compared with healthy controls (486 (SD 88) v 162 (38) ng/g creatinine) and increased further in the patients (to 1007 (212) ng/g creatinine) during application of a cold stimulus sufficient to induce digital vasoconstriction. Consistent with an increase in platelet-vascular interactions in vivo, excretion of a prostacyclin metabolite was also significantly increased (p less than 0.005) in the patients with systemic sclerosis (248 (39) v 112 (10) ng/g creatinine) and tended to increase further on cooling. Biosynthesis of thromboxane is increased in patients with systemic sclerosis and may exacerbate digital vasospasm that such patients develop when cold. This observation and the concomitant increase in the formation of prostacyclin provide a rationale for evaluating compounds that prevent the synthesis of thromboxane A2 or inhibit its action while preserving the potential homoeostatic role of prostacyclin.

Full text

PDF
1039

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertele V., De Gaetano G. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin. Eur J Pharmacol. 1982 Dec 3;85(3-4):331–333. doi: 10.1016/0014-2999(82)90220-5. [DOI] [PubMed] [Google Scholar]
  2. Coffman J. D., Rasmussen H. M. Effect of thromboxane synthetase inhibition in Raynaud's phenomenon. Clin Pharmacol Ther. 1984 Sep;36(3):369–373. doi: 10.1038/clpt.1984.189. [DOI] [PubMed] [Google Scholar]
  3. Di Minno G., Silver M. J., Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood. 1983 Jun;61(6):1081–1085. [PubMed] [Google Scholar]
  4. Ettinger W. H., Wise R. A., Schaffhauser D., Wigley F. M. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. Am J Med. 1984 Sep;77(3):451–456. doi: 10.1016/0002-9343(84)90101-3. [DOI] [PubMed] [Google Scholar]
  5. FitzGerald G. A., Brash A. R., Falardeau P., Oates J. A. Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest. 1981 Nov;68(5):1272–1276. doi: 10.1172/JCI110373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. FitzGerald G. A., Lawson J., Blair I. A., Brash A. R. Analysis of urinary metabolites of thromboxane and prostacyclin by negative-ion chemical-ionization gas chromatography/mass spectrometry. Adv Prostaglandin Thromboxane Leukot Res. 1985;15:87–90. [PubMed] [Google Scholar]
  7. FitzGerald G. A., Oates J. A., Hawiger J., Maas R. L., Roberts L. J., 2nd, Lawson J. A., Brash A. R. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983 Mar;71(3):676–688. doi: 10.1172/JCI110814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. FitzGerald G. A., Pedersen A. K., Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation. 1983 Jun;67(6):1174–1177. doi: 10.1161/01.cir.67.6.1174. [DOI] [PubMed] [Google Scholar]
  9. FitzGerald G. A., Reilly I. A., Pedersen A. K. The biochemical pharmacology of thromboxane synthase inhibition in man. Circulation. 1985 Dec;72(6):1194–1201. doi: 10.1161/01.cir.72.6.1194. [DOI] [PubMed] [Google Scholar]
  10. FitzGerald G. A., Smith B., Pedersen A. K., Brash A. R. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med. 1984 Apr 26;310(17):1065–1068. doi: 10.1056/NEJM198404263101701. [DOI] [PubMed] [Google Scholar]
  11. Freedman R. R., Ianni P. Role of cold and emotional stress in Raynaud's disease and scleroderma. Br Med J (Clin Res Ed) 1983 Nov 19;287(6404):1499–1502. doi: 10.1136/bmj.287.6404.1499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. HALPERN A., KUHN P. H., SHAFTEL H. E., SAMUELS S. S., SHAFTEL N., SELMAN D., BRICH H. G. Raynaud's disease, Raynaud's phenomenon, and serotonin. Angiology. 1960 Jun;11:151–167. doi: 10.1177/000331976001100301. [DOI] [PubMed] [Google Scholar]
  13. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hirsh P. D., Hillis L. D., Campbell W. B., Firth B. G., Willerson J. T. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med. 1981 Mar 19;304(12):685–691. doi: 10.1056/NEJM198103193041201. [DOI] [PubMed] [Google Scholar]
  15. Jones E. W., Hawkey C. J. A thromboxane synthetase inhibitor in Raynaud's phenomenon. Prostaglandins Leukot Med. 1983 Sep;12(1):67–71. doi: 10.1016/0262-1746(83)90068-9. [DOI] [PubMed] [Google Scholar]
  16. Jones R. L., Wilson N. H., Armstrong R. A., Peesapati V., Smith G. M. Effects of thromboxane antagonist EP 045 on platelet aggregation. Adv Prostaglandin Thromboxane Leukot Res. 1983;11:345–350. [PubMed] [Google Scholar]
  17. Kahaleh M. B., Osborn I., Leroy E. C. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med. 1982 May;96(5):610–613. doi: 10.7326/0003-4819-96-5-610. [DOI] [PubMed] [Google Scholar]
  18. Kaplan K. L., Owen J. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood. 1981 Feb;57(2):199–202. [PubMed] [Google Scholar]
  19. Lawson J. A., Brash A. R., Doran J., FitzGerald G. A. Measurement of urinary 2,3-dinor-thromboxane B2 and thromboxane B2 using bonded-phase phenylboronic acid columns and capillary gas chromatography--negative-ion chemical ionization mass spectrometry. Anal Biochem. 1985 Nov 1;150(2):463–470. doi: 10.1016/0003-2697(85)90536-6. [DOI] [PubMed] [Google Scholar]
  20. Luderer J. R., Nicholas G. G., Neumyer M. M., Riley D. L., Vary J. E., Garcia G., Schneck D. W. Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon. Clin Pharmacol Ther. 1984 Jul;36(1):105–115. doi: 10.1038/clpt.1984.147. [DOI] [PubMed] [Google Scholar]
  21. Needleman P., Raz A., Ferrendelli J. A., Minkes M. Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets. Proc Natl Acad Sci U S A. 1977 Apr;74(4):1716–1720. doi: 10.1073/pnas.74.4.1716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Patrono C., Ciabattoni G., Pinca E., Pugliese F., Castrucci G., De Salvo A., Satta M. A., Peskar B. A. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980 Feb 1;17(3-4):317–327. doi: 10.1016/0049-3848(80)90066-3. [DOI] [PubMed] [Google Scholar]
  23. Patrono C., Ciabattoni G., Pugliese F., Pierucci A., Blair I. A., FitzGerald G. A. Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest. 1986 Feb;77(2):590–594. doi: 10.1172/JCI112341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Roberts L. J., 2nd, Sweetman B. J., Oates J. A. Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites. J Biol Chem. 1981 Aug 25;256(16):8384–8393. [PubMed] [Google Scholar]
  25. Rodnan G. P., Myerowitz R. L., Justh G. O. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 1980 Nov;59(6):393–408. doi: 10.1097/00005792-198011000-00001. [DOI] [PubMed] [Google Scholar]
  26. Roy L., Knapp H. R., Robertson R. M., FitzGerald G. A. Endogenous biosynthesis of prostacyclin during cardiac catheterization and angiography in man. Circulation. 1985 Mar;71(3):434–440. doi: 10.1161/01.cir.71.3.434. [DOI] [PubMed] [Google Scholar]
  27. Zahavi J., Hamilton W. A., O'Reilly M. J., Leyton J., Cotton L. T., Kakkar V. V. Plasma exchange and platelet function in Raynaud's phenomenon. Thromb Res. 1980 Jul 1;19(1-2):85–93. doi: 10.1016/0049-3848(80)90406-5. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES